AU2001253119B2 - A gene differentially expressed in breast and bladder cancer and encoded polypeptides - Google Patents

A gene differentially expressed in breast and bladder cancer and encoded polypeptides Download PDF

Info

Publication number
AU2001253119B2
AU2001253119B2 AU2001253119A AU2001253119A AU2001253119B2 AU 2001253119 B2 AU2001253119 B2 AU 2001253119B2 AU 2001253119 A AU2001253119 A AU 2001253119A AU 2001253119 A AU2001253119 A AU 2001253119A AU 2001253119 B2 AU2001253119 B2 AU 2001253119B2
Authority
AU
Australia
Prior art keywords
amino acids
seq
peptide
epitope
peptide epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001253119A
Other languages
English (en)
Other versions
AU2001253119A1 (en
AU2001253119A2 (en
Inventor
Melinda A. Borrello
Elizabeth E. Evans
Maurice Zauderer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of AU2001253119A1 publication Critical patent/AU2001253119A1/en
Publication of AU2001253119A2 publication Critical patent/AU2001253119A2/en
Application granted granted Critical
Publication of AU2001253119B2 publication Critical patent/AU2001253119B2/en
Priority to AU2006202984A priority Critical patent/AU2006202984B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2001253119A 2000-04-04 2001-04-04 A gene differentially expressed in breast and bladder cancer and encoded polypeptides Ceased AU2001253119B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006202984A AU2006202984B2 (en) 2000-04-04 2006-07-12 A gene differentially expressed in breast and bladder cancer and encoded polypeptides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19446300P 2000-04-04 2000-04-04
US60/194,463 2000-04-04
PCT/US2001/010855 WO2001074859A2 (en) 2000-04-04 2001-04-04 A gene differentially expressed in breast and bladder cancer and encoded polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2006202984A Division AU2006202984B2 (en) 2000-04-04 2006-07-12 A gene differentially expressed in breast and bladder cancer and encoded polypeptides

Publications (3)

Publication Number Publication Date
AU2001253119A1 AU2001253119A1 (en) 2002-01-03
AU2001253119A2 AU2001253119A2 (en) 2003-03-27
AU2001253119B2 true AU2001253119B2 (en) 2006-04-13

Family

ID=22717696

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001253119A Ceased AU2001253119B2 (en) 2000-04-04 2001-04-04 A gene differentially expressed in breast and bladder cancer and encoded polypeptides
AU5311901A Pending AU5311901A (en) 2000-04-04 2001-04-04 A gene differentially expressed in breast and bladder cancer and encoded polypeptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU5311901A Pending AU5311901A (en) 2000-04-04 2001-04-04 A gene differentially expressed in breast and bladder cancer and encoded polypeptides

Country Status (10)

Country Link
US (3) US7268207B2 (enExample)
EP (1) EP1272636B8 (enExample)
JP (1) JP2004502408A (enExample)
CN (2) CN101643732A (enExample)
AT (1) ATE404669T1 (enExample)
AU (2) AU2001253119B2 (enExample)
CA (1) CA2413211A1 (enExample)
DE (1) DE60135315D1 (enExample)
NZ (1) NZ522282A (enExample)
WO (1) WO2001074859A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001253119B2 (en) * 2000-04-04 2006-04-13 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7135278B1 (en) 2000-09-29 2006-11-14 University Of Rochester Method of screening for therapeutics for infectious diseases
US20020164346A1 (en) * 2001-02-14 2002-11-07 Nicolette Charles A. Altered peptide ligands
AU2002322280A1 (en) 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US7563882B2 (en) 2002-06-10 2009-07-21 University Of Rochester Polynucleotides encoding antibodies that bind to the C35 polypeptide
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
US20040210037A1 (en) * 2003-03-28 2004-10-21 Vaccinex, Inc. Targeted MHC class I alpha3 vaccine delivery systems
US20050042218A1 (en) * 2003-07-10 2005-02-24 Vaccinex, Inc. MHC class I - peptide-antibody conjugates with modified beta2-microglobulin
AU2004296184B2 (en) * 2003-12-04 2010-12-16 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US20050260659A1 (en) * 2004-04-23 2005-11-24 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
WO2007149586A2 (en) * 2006-06-22 2007-12-27 Vaccinex, Inc. Anti-c35 antibodies for treating cancer
WO2008103392A2 (en) * 2007-02-21 2008-08-28 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cdid molecules
NZ584848A (en) 2007-09-28 2012-09-28 Intrexon Corp Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
NZ586544A (en) 2007-12-26 2012-07-27 Vaccinex Inc Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
CN107619804A (zh) 2009-01-08 2018-01-23 阿尔伯爱因斯坦医学有限公司 具有细胞壁结合神经酰胺类糖脂的细菌疫苗及其应用
US8808693B2 (en) * 2009-04-01 2014-08-19 The University Of British Columbia Semaphorin 3C (Sema3C) inhibitor therapeutics, methods, and uses
WO2011038142A2 (en) 2009-09-24 2011-03-31 The Regents Of The University Of California Bladder cancer specific ligand peptides
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
TWI765875B (zh) * 2015-12-16 2022-06-01 美商磨石生物公司 新抗原辨識、製造及用途
CA3073812A1 (en) * 2017-09-05 2019-03-14 Gritstone Oncology, Inc. Neoantigen identification for t-cell therapy
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
US12359253B2 (en) 2018-04-09 2025-07-15 The Board Of Trustees Of The Leland Stanford Junior University Method of in situ gene sequencing
KR102318018B1 (ko) 2019-07-05 2021-10-28 한국생산기술연구원 마이크로 제품 제작용 맨드렐 제작 방법, 마이크로 제품 제작용 몰드 제작 방법 및 마이크로 제품 제작용 몰드
WO2021076770A1 (en) * 2019-10-18 2021-04-22 The Board Of Trustees Of The Leland Stanford Junior University Clinical- and industrial-scale intact-tissue sequencing
CN115407064B (zh) * 2021-05-26 2025-09-23 复旦大学附属肿瘤医院 肿瘤干细胞血管拟态标志物tem8在制备诊断试剂和试剂盒中的用途
US20240409582A1 (en) * 2022-08-23 2024-12-12 The University of North Texas Health Sciences Cente Design and characterization of inhibitory peptides (ipeps) derived from of mien 1 protein sequence

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3869400A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human cancer associated gene sequences and polypeptides

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0581600A (ja) * 1991-04-18 1993-04-02 Fujitsu Ltd 双曲線航法システムにおけるシステム監視処理方式
SG52492A1 (en) 1992-08-07 1998-09-28 Cytel Corp Hla binding peptides and their uses
JP3908271B2 (ja) 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
US5856131A (en) * 1997-02-24 1999-01-05 Incyte Pharmaceuticals, Inc. Human selenoprotein
US7026447B2 (en) * 1997-10-09 2006-04-11 Human Genome Sciences, Inc. 53 human secreted proteins
CA2316397A1 (en) 1997-12-24 1999-07-08 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
AU2342299A (en) * 1998-01-26 1999-08-09 Genquest Inc. Compositions and methods for detecting and treating breast cancer
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
WO2001040269A2 (en) 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
AU2001253119B2 (en) * 2000-04-04 2006-04-13 University Of Rochester A gene differentially expressed in breast and bladder cancer and encoded polypeptides
EP1274852A2 (en) 2000-04-12 2003-01-15 University Of Rochester Targeted vaccine delivery systems
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
CN1306272C (zh) * 2000-11-17 2007-03-21 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
US7563882B2 (en) 2002-06-10 2009-07-21 University Of Rochester Polynucleotides encoding antibodies that bind to the C35 polypeptide
US20050042218A1 (en) 2003-07-10 2005-02-24 Vaccinex, Inc. MHC class I - peptide-antibody conjugates with modified beta2-microglobulin
AU2004296184B2 (en) * 2003-12-04 2010-12-16 Vaccinex, Inc. Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3869400A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human cancer associated gene sequences and polypeptides

Also Published As

Publication number Publication date
NZ522282A (en) 2005-03-24
WO2001074859A2 (en) 2001-10-11
US7910551B2 (en) 2011-03-22
DE60135315D1 (de) 2008-09-25
CN1610743A (zh) 2005-04-27
ATE404669T1 (de) 2008-08-15
US20020155447A1 (en) 2002-10-24
CN101643732A (zh) 2010-02-10
US7268207B2 (en) 2007-09-11
US20090312263A1 (en) 2009-12-17
EP1272636B1 (en) 2008-08-13
JP2004502408A (ja) 2004-01-29
EP1272636A2 (en) 2003-01-08
US20070081942A1 (en) 2007-04-12
WO2001074859A3 (en) 2002-03-28
AU5311901A (en) 2001-10-15
CA2413211A1 (en) 2001-10-11
EP1272636B8 (en) 2008-10-08

Similar Documents

Publication Publication Date Title
AU2001253119B2 (en) A gene differentially expressed in breast and bladder cancer and encoded polypeptides
US7750125B2 (en) Antibodies that bind to the C35 polypeptide
AU2001253119A2 (en) A gene differentially expressed in breast and bladder cancer and encoded polypeptides
CA2345817C (en) Novel methods for therapeutic vaccination
EP0752876B1 (en) Monoclonal anbibodies which bind to tumor rejection antigen precursor mage-1, recombinant mage-1, and mage-1 derived immunogenic peptides
JPH04501719A (ja) ポリペプチド
JP2002541833A (ja) ４９個のヒト分泌タンパク質
AU781925B2 (en) T-cell receptor gamma alternate reading frame protein, (TARP) and uses thereof
AU2006202984B2 (en) A gene differentially expressed in breast and bladder cancer and encoded polypeptides
EP1788085A1 (en) A gene differentially expressed in breast and bladder cancer and encoded polypeptides
ZA200102603B (en) Novel methods for therapeutic vaccination.
NZ548918A (en) Gene differentially expressed in breast and bladder cancer and encoded polypeptides
CN101173285A (zh) 在乳腺癌和膀胱癌中差异表达的基因及编码多肽
JP2002538807A (ja) ５０個のヒト分泌タンパク質

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 30 JAN 2003

MK14 Patent ceased section 143(a) (annual fees not paid) or expired